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Background: One of the most commonly used vectors for gene therapy is the adenoviral vector; its ability to
tightly regulate transgene expression is critical for optimizing therapeutic outcomes. The tetracycline-regulated
system (especially the Tet-On system) for gene expression is one of the most valuable tools for controlling gene
expression. The major problem of an adenoviral vector carrying a Tet-On system is suboptimal regulation of
transgene expression.
Results: We constructed a single adenoviral vector carrying in its E1 region a novel “all-in-one” Tet-On system with
an autoregulatory loop. This system had improved Dox-inducible gene expression in terms of low basal expression,
high induced expression and high responsiveness to Dox. To our knowledge, this is the first reported adenovirus-
based, all-in-one Tet-On system with an autoregulatory loop inserted into a single region of adenoviral genome.
This system was further tested by inducible expression of soluble tumor necrosis factor-related apoptosis-inducing
ligand (sTRAIL). The adenovirus that expressed soluble TRAIL under the control of this novel Tet-On system showed
tumor-derived cells inhibitory activity in SW480 cells only under induced conditions.
Conclusions: Our novel, single adenoviral vector carrying in its E1 region an all-in-one Tet-On system with an
autoregulatory loop displayed tight regulation of transgene expression in vitro. This system has great potential for a
variety of applications, including gene therapy and the study of gene function.
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The adenovirus (Ad) vector is one of the most com-
monly used vectors for gene therapy. The tightly regu-
lated expression of transgenes by adenoviruses is very
important for optimizing therapeutic outcomes. Several
regulated expression systems have been developed in re-
cent years. The most widely used system in gene therapy
investigations is the Tet-inducible system [1-6] with its
two variants, Tet-Off [7] and Tet-On [8]. Briefly, in the
Tet-Off system, by using the tetracycline transactivator
(tTA) protein, transcription is turned off in the presence
of tetracycline. In the Tet-On system, by using the re-
verse Tet transactivator (rtTA) fusion protein, transcrip-
tion is turned on in the presence of tetracycline. In* Correspondence: hbxia2001@163.com
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unless otherwise stated.general, the Tet-On system is preferred over Tet-Off for
gene therapeutic applications because its responsiveness
is faster and because there is no need for continuous
pharmacological treatment after gene expression termin-
ation. One of the major problems of the original Tet-On
system, the leakiness in the absence of the inducer, was
solved by taking advantage of several modified, so-called
“second generation” rtTAs (rtTA2S-S2, rtTA2S-M2) [9-11],
and co-expression of a Tet-controlled transcriptional silen-
cer (tTS or TetR-KRAB) [12-14].
The being said, if a single Ad vector could carry a Tet-On
regulation system, it would be more practical and would
facilitate the widespread application of that Ad vector.
Some studies used an IRES-mediated bicistronic unit for
rtTA and tTS expression in the Ad vector context; how-
ever, no consistent results were obtained in terms of the
regulational properties of this system [15,16]. Mizuguchi
et al. produced an Ad-mediated Tet-On system thathis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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the gene of interest, rtTA2S-S2, and tTS, in the E1 dele-
tion region, the E3 deletion region, and the region be-
tween E4 and 3′ITR, respectively, and displayed improved
inducible gene regulation. However, the space for thera-
peutic genes was compromised in their system [15].
In this study, by utilizing a tetracycline-controlled
transcriptional silencer (tTS or TetR-KRAB) and the lat-
est version of rtTA (rtTA2S-M2), we constructed a sin-
gle adenoviral vector carrying an all-in-one Tet-On
system with an autoregulatory loop in the E1 region to
improve the regulational properties of the Ad-mediated
Tet-On system. This system was further tested by indu-
cible expression of soluble tumor necrosis factor-related
apoptosis-inducing ligand (sTRAIL) in SW480 cells and




HEK 293, a human embryonic kidney cell line (ATCC,
CRL-1573), SW480, a human colon carcinoma cell line
(ATCC, CCL-228), and U87 MG, a human glioblastoma
cell line (ATCC, HTB-14), were cultured in Dulbecco’s
Modified Eagle’s Medium (DMEM) (Gibco, Grand Island,
NY) containing 10% (v/v) newborn calf serum (NCS)
(Gibco, Grand Island, NY) at 37°C in a 5% CO2 atmos-
phere. CHO-K1, a Chinese hamster ovary cell line (ATCC,
CCL-61), was maintained in RPMI 1640 medium (Gibco,
Grand Island, NY), supplemented with 10% (v/v) NCS at
37°C in a 5% CO2 atmosphere.
The construction of the Bi-Tet-On system
The plasmid pTRE2pur carrying the TRE-PminCMV
element and the plasmid pTet-On containing the rtTA
element were purchased from Clontech Laboratories
(Mountain View, CA). The vector pLVCT-tTR-KRAB
containing the TetR-KRAB element and the vector
pLVCT-rtTR-KRAB-2SM2 carrying the rTetR-M2-KRAB
were purchased from Addgene (Cambridge, MA). The
plasmid pTight-PminCMV, pKpnI-CMV-sv40pA, the pAd5-
E1 shuttle and the adenoviral backbone plasmid carrying
an eGFP expression cassette in the E3 region were all kept
in our lab.
The TetR-KRAB cDNA was obtained by PCR from the
pLVCT-tTR-KRAB using a pair of primers, P1: AATCGA-
TATGGCTAGATTAGATAAA and P2: TTCTAGAT
TAAACTGATGATTTGAT. The italic primer se-
quences indicate ClaI and XbaI restriction sites at both
ends.
The rtTA cDNA was amplified by PCR from the plas-
mid pTet-On using the primers P3: TGAATTCATGTC
TAGATTAGATAAA and P4: ACTAGTCTACCCACCG
TACTCGTC. The italic primer sequences indicate EcoRIand SpeI restriction sites at both ends. The rTetR-M2
was obtained by PCR from the plasmid pLVCT-rtTR-
KRAB-2SM2 using the following primers: P5: TGAATT
CATGGCTAGACTGGACAAGAG and P6: CAGATCTC
GACCCACTTTCACATTTAA. The primers included
EcoRI and BglII restriction sites at both ends. Lastly, the
3 × VP16 region was obtained by PCR using P7: GGA
TCCGGCTCGCCGGCCGACGCCCTTGACGATTTTG
ACTTAGACATGCTCCCAGCCGATGCCCTTGACGA
CTTTGACCT and P8: ACTAGTTTACCCGGGGAG
CATGTCAAGGTCAAAATCGTCAAGAGCGTCAGCA
GGCAGCATATCAAGGTCAAAGTCGTCAA. The italic
primer sequences indicate BamHI and SpeI restriction
sites, respectively, at both ends. Subsequently, the rtTA-
M2 fragment was ligated with 3 × VP16 fragment, and the
resultant plasmid was named p-rtTA2S-M2.
The rtTA cDNA was cloned into pKpnI-CMV-sv40pA by
EcoRI and SpeI sites, the obtained plasmid was called
pKpnI-CMV-rtTA-sv40pA. rtTA2S-M2 cDNA was inserted
into the pKpnI-CMV-sv40pA at EcoRI and SpeI sites, the
resultant plasmid was named pKpnI-CMV-rtTA2S-M2-
sv40pA. TetR-KRAB cDNA was inserted into the pKpnI-
CMV-sv40pA at ClaI and XbaI sites, the resultant plasmid
was called pKpnI-CMV-KRAB-sv40-pA. Then the TRE-
PminCMV fragment derived from pTRE2pur was ligated
into the pAd5-E1 shuttle at XhoI and EcoRI sites, and the
obtained vector was called pAd5E1-TRE-PminCMV-shut-
tle. Using a similar strategy, the vector pAd5E1-TRE-
PTminCMV-shuttle, which contains the Tight-PminCMV
fragment derived from the pTight-PminCMV instead of
the PminCMV element at the KpnI and EcoRI sites, was
obtained. Then the KpnI site was removed from both
plasmids. The plasmid pAd5-CMV-rtTA-TRE-pminCMV-
shuttle was generated by inserting the fragment CMV-
rtTA-sv40pA from pKpnI-CMV-rtTA-sv40pA, which was
digested by KpnI and XhoI into the KpnI and SalI sites of
pAd5E1-TRE-pminCMV-shuttle. The plasmid pAd5-
CMV-rtTA2S-M2-TRE-pminCMV-shuttle was obtained
by the same method.
pCMV-PminCMV-rtTA2S-M2-sv40pA was generated
by inserting the fragments PminCMV and rtTA2S-M2
into XhoI-EcoRI-SpeI sites of the pAd5-E1 sequentially.
pAd5-Bi-Tet-On was generated by inserting the frag-
ment PminCMV-rtTA2S-M2-sv40pA derived from the
pCMV-PminCMV-rtTA2S-M2-sv40pA into NotI and
XhoI sites of the pAd5E1-TRE-pTminCMV-shuttle in
the opposite direction. The pAd5-KRAB-Bi-Tet-On was
generated by cloning the fragment CMV-TetR-KRAB
derived from pKpnI-CMV-KRAB-sv40pA into the KpnI
and NotI sites of pAd5-Bi-Tet-On. pAd5-CMV-rtTA-
TRE-PminCMV contained two expression cassettes with
the two promoters facing the same direction. In this
system, rtTA was used as a transactivator and TRE-
PminCMV controlled the target gene expression. In
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tem, pAd5-CMV-rtTA2S-M2-TRE-PminCMV included
rtTA2S-M2 rather than rtTA. pAd5-Bi-Tet-On was a bi-
directional system, in which two promoters were placed
on both sides of TRE in the opposite direction, and
rtTA2S-M2 was expressed by the left cassette, which
could be activated by the products of itself. pAd5-
KRAB-Bi-Tet-On was similar to the pAd5-Bi-Tet-On sys-
tem but a TetR-KRAB expression cassette was inserted at
the 5′-terminal of the system.
Luciferase activity assay
A dual-luciferase system was used to normalize cell
number and transfection efficiency. HEK293 cells or
CHO-K1 cells were plated into 24-well plates until the
cell density reached 70%. Then the vectors and the
Renilla luciferase as internal reference plasmid pRL-
CMV (Promega, Madison, WI) were co-transfected into
the cells using Lipofectamine™ 2000 Reagent (Invitrogen,
Carlsbad, CA) according to the manufacturer’s protocol.
Four hours later, the cells were cultured in fresh medium
in the presence of 2 μg of Doxycycline/ml (Dox, Sigma-
Aldrich, St. Louis, MO); 48 hours post-transfection, the
cells were collected for a luciferase activity assay using a
dual-luciferase assay kit (Promega, Madison, WI). The
normalized luciferase activity was obtained by using the
formula: Normalized luciferase value = Fly luciferase
value/Renilla luciferase value.
Adenovirus production
An adenovirus expressing sTRAIL in the E1 region and
controlled by a Tet-On promoter was produced by co-
transfecting PacI linearized p-Ad5-KRAB-Bi-Tet-On-
sTRAIL and the adenoviral backbone carrying an eGFP
expression cassette in the E3 region into HEK293 cells
grown in 60 mm dishes. Ten days post-transfection, the
viral lysates were harvested and further propagated in
HEK293 cells and were purified by cesium chloride
gradient methods. The resultant adenovirus was named
Ad5-KRAB-Bi-Tet-On-sTRAIL-eGFP. Ad5-KRAB-Bi-Tet-
On-sTRAIL-eGFP carrying an eGFP expression cassette in
the E3 region under the control of a CMV promoter was
prepared as previously described [17]. The virus particle
titers were detected by spectrophotometry at an absorb-
ance of 260 nm.
The assay of cell growth inhibition in vitro
SW480 cells (1 × 104/well) were seeded into a 96-well
plate the day prior to transduction with adenoviruses
(250 multiplicity of infection (MOI)). Four hours post-
transduction, the cells were cultured in fresh medium in
the presence or absence of 2 μg Dox/ml. Cell growth in-
hibition was assayed 72 h post infection by an MTT (3-(4,
5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide)assay (Sigma, Saint Louis, MO), which was conducted ac-
cording to the manufacturer’s protocol. MTT assay results
were determined by measuring OD values at A570. U87
MG cells were transduced with different adenoviruses
with 100 MOI.
Statistics
Results are reported as the mean ± standard deviation
(SD) and statistical analyses were performed using the
Statistical Package for the Social Sciences (SPSS) soft-
ware, version 13 (SPSS Inc., Chicago, Illinois). Differ-
ences between control and experimental groups were
analyzed using one-way analysis of variance between
groups (ANOVA/LSD), and a P-value of 0.05 or less in-
dicated a statistically significant difference.
Results
Generation of a novel adenoviral E1 shuttle-based,
all-in-one Tet-On system with an autoregulatory loop
The major problem with an adenoviral vector carrying a
Tet-On system is the suboptimal regulation of transgene
expression. To address this problem, we first constructed
three shuttle vectors, pAd5-CMV-rtTA-TRE-PminCMV
(Figure 1A), pAd5-CMV-rtTA2S-M2-TRE-PminCMV
(Figure 1B), and pAd5-Bi-Tet-On (Figure 1C). Based on
these vectors, we then constructed an adenoviral E1
shuttle-based, all-in-one Tet-On system with a bidirec-
tional autoregulatory loop, named pAd5-KRAB-Bi-Tet-On
(Figure 1D). The final vector contained rtTA2S-M2, a new
version of rtTA that has minimal basal activity and
increased doxycycline sensitivity, and a tetracycline-
controlled transcriptional silencer, TetR-KRAB.
Improved regulational properties of the novel Tet-On
system
The novel Ad5-KRAB-Bi-Tet-On system was first evalu-
ated by expressing the reporter eGFP in HEK293 cells.
Compared to controls, pAd5-KRAB-Bi-Tet-On-eGFP
displayed minimal eGFP expression in the absence of
Dox and a similar expression level of eGFP in the pres-
ence of 2 μg Dox/ml (Figure 2).
The two most important criteria for evaluating a regu-
lation system are the regulation factor (the ratio of max-
imum transgene expression level to minimum transgene
expression level) and the maximum induced transgene
expression level. To quantify these two criteria in the
novel system, a reporter gene luciferase was cloned into
each plasmid. The regulation factors of pAd5-CMV-
rtTA2S-M2-TRE-PminCMV-luciferase, pAd5-Bi-Tet-On-
Luciferase and pAd5-KRAB-Bi-Tet-On-Luciferase were
34, 41 and 137, respectively (Figure 3A). The normalized
basal luciferase production of each of the three vectors in
the absence of Dox was 0.2420 ± 0.0017, 0.0394 ± 0.0101
and 0.0141 ± 0.0011, and the induced (maximum) luciferase
Figure 1 Illustrations of different Tet-On inducible expression systems in the context of Ad5 E1 shuttle vector. (A) pAd5-CMV-rtTA-TRE-
PminCMV contains two expression cassettes with rtTA and the transgene controlled by two different promoters, pCMV and TRE-PminCMV,
respectively, in the same direction. (B) pAd5-CMV-rtTA2S-M2-TRE-PminCMV is similar to pAd5-CMV-rtTA-TRE-PminCMV except that rtTA was
replaced by rtTA2S-M2. (C) pAd5-Bi-Tet-On contains two promoters placed on both sides of TRE, forming an autoregulatory loop. (D) pAd5-KRAB-
Bi-Tet-On contains an additional TetR-KRAB expression cassette compared to pAd5-Bi-Tet-On.
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1.0734, 1.5646 ± 0.0324 and 1.9226 ± 0.0332, respectively
(Figure 3A). To our knowledge, pAd5-KRAB-Bi-Tet-On is
the first reported adenoviral shuttle-based, all-in-one Tet-
On system with a bidirectional autoregulatory loop that
shows optimal regulated transgene production (the gener-
ally accepted standard is > 30). Additionally, as expected,
TetR-KRAB in pAd5-KRAB-Bi-Tet-On further reduced
the leakage of transgene expression in the absence of Dox
(Figure 3A).
Next, we evaluated pAd5-KRAB-Bi-Tet-On’s respon-
siveness to Dox. pAd5-KRAB-Bi-Tet-On-Luciferase was
transfected into CHO-K1 cells followed by the additionFigure 2 Regulational expression of eGFP by the novel Tet-On system
systems as indicated and were maintained in the presence or absence of 2 μg
controls, respectively. Forty-eight hours after transfection, images were taken wof Dox in different concentrations. Luciferase activity was
measured in cell lysates every 4 h. The induction of lucif-
erase expression from pAd5-KRAB-Bi-Tet-On-Luciferase
was both time-dependent (Figure 3B) and dose-dependent
(Figure 3C), with the maximal level of luciferase expres-
sion achieved with 2 μg Dox/ml after 40 h of induction.
Adenoviral vector encoding sTRAIL under the control of
the novel all-in-one Tet-On system
To investigate whether the novel Tet-On system could
be suitable for regulating therapeutic genes in anti-
tumor approaches, we constructed an adenovirus that
carries soluble TRAIL under the control of our novel. HEK293 cells were transfected with different inducible expression
Dox/ml. pCMV-eGFP and pAd5-E1 were used as positive and negative
ith a fluorescent microscope (200 × view field).
Figure 3 Regulational luciferase expression by the novel Tet-On system. (A) The comparison of different Tet-On systems. 293 cells were
transfected with different Tet-On systems as well as the negative control pAd5-E1 and the positive control pCMV-Luciferase, in the presence or
absence of Dox (2 μg Dox/ml). Forty-eight hours post-transfection, the activities of firefly luciferase and the internal control, Renilla luciferase, were
quantified. The ratio of firefly luciferase to Renilla luciferase activity (FL/RL) was used to represent normalized luciferase activity. Experiments were
repeated three times; *P < 0.05. (B) Time course of luciferase expression by pAd5-KRAB-Bi-Tet-On-Luciferase following Dox induction. CHO-K1 cells
were transfected with pAd5-KRAB-Bi-Tet-On-Luciferase in the presence of 2 μg Dox/ml. Cells were collected every 4 h and normalized luciferase
activities were obtained. Experiments were repeated three times. Data represent mean ± SD. (C) Dose–response curve demonstrating regulational
expression of luciferase by the pAd5-KRAB-Bi-Tet-On vector. CHO-K1 cells were transfected with pAd5-KRAB-Bi-Tet-on-Luciferase in the presence
of Dox at the final concentrations of 10 ng/ml, 100 ng/ml, 1000 ng/ml, 2000 ng/ml, 4000 ng/ml, 8000 ng/ml, and 10000 ng/ml. Forty-eight hours
post-transfection, the cells were collected, and normalized luciferase activities were obtained. Experiments were repeated three times. Data
represent mean ± SD.
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duces apoptosis in a variety of cancer cells [18,19]. How-
ever, there is evidence that TRAIL has potential toxicity
in some normal human cells [20-23]. Therefore, it is es-
sential that the expression of TRAIL be strictly and con-
sistently regulated in gene therapy protocols, so its
concentration is within a ‘therapeutic window’ that max-
imizes treatment effects and minimizes the deleterious
consequences of overexpression.
As a proof-of-principle, pAd5-KRAB-Bi-Tet-On, the
adenoviral shuttle vector carrying the inducible expression
system, was restricted by XhoI and XbaI followed by
ligation with a sTRAIL fragment. The resultant plasmid
was called pAd5-KRAB-Bi-Tet-On-sTRAIL. Then we co-
transfected PacI-linearized pAd5-KRAB-Bi-Tet-On-sTRAIL
and PacI-digested adenoviral backbone carrying an eGFP
expression cassette in the E3 region into HEK 293 cells, to
generate the recombinant adenovirus Ad5-E1-KRAB-Bi-
Tet-On-sTRAIL-E3-eGFP. In addition, a non-inducible
adenovirus carrying sTRAIL, named Ad5-E1-sTRAIL-E3-
eGFP, was generated as a control adenovirus.After propagation in the packaging cell line HEK293
(in the absence of Dox), the yield of Ad5-KRAB-Bi-Tet-
On-sTRAIL was evaluated. Interestingly, it was found
that the titer / infectious unit (IU) of Ad5-KRAB-Bi-Tet-
On-sTRAIL was only about 35% of the control Ad5-E1-
sTRAIL-E3-eGFP (Table 1). The lower viral particle/IU
of the virus compared to that of the control might be at-
tributable to the improved Ad packaging (due to the low
basal level) and hence low cytotoxicity of sTRAIL.
SW480 cell lines were then transduced with Ad5-E1-
eGFP, Ad5-E1-sTRAIL-E3-eGFP and Ad5-E1-KRAB-Bi-
Tet-On-sTRAIL-E3-eGFP (250 MOI). And U87 MG
cells, which are TRAIL- insensitive [24-26], were used as
the negative control. In order to achieve the similar in-
fection efficiency to SW480 cells (approximately 90%),
U87 MG cells was transduced with 100 MOI adenovi-
ruses. Cell death was monitored by MTT assay three
days post-transduction. No cytotoxicity was observed on
SW480 cells with Ad5-E1-eGFP or Ad5-E1-KRAB-Bi-
Tet-On-sTRAIL-E3-eGFP in the absence of Dox,
whereas the cells transduced with Ad5-E1-sTRAIL-E3-
Table 1 The comparison of two types of viruses in titer and activity
Name of virus Titer (pt/mL) Activity (IU/mL) Titer/Activity (pt/IU) Titer/Activity (mean ± SD)
Ad5-E1-KRAB-Bi-Tet-On-sTRAIL-E3-eGFP 1.9 × 1012 2.5 × 1010 76 55.67 ± 20.00
3.0 × 1012 5.5 × 1010 55
1.8 × 1012 5.0 × 1010 36
Ad5-E1-sTRAIL-E3-eGFP 2.2 × 1012 1.0 × 1010 220 160.33 ± 51.73*
1.6 × 1012 1.25 × 1010 128
2.0 × 1012 1.5 × 1010 133
*P < 0.05.
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in the presence of Dox showed increased cell death
(Figure 4A). Similarly, Ad5-E1-eGFP or Ad5-E1-KRAB-
Bi-Tet-On-sTRAIL-E3-eGFP had no effects on U87 MG
cells in the absence of Dox; however, TRAIL-insensitive
U87 MG cells showed less cell death compared with
SW480 cells after being transduced with Ad5-E1-sTRAIL-
E3-eGFP or Ad5-E1-KRAB-Bi-Tet-On-sTRAIL-E3-eGFP
in the presence of Dox (Figure 4B). Interestingly, Ad5-E1-
sTRAIL-E3-eGFP, the vector with stable sTRAIL expres-
sion, revealed greater suppressor activity on SW480 cells
in the presence of 2 μg Dox/ml than in the absence of
Dox (P < 0.01). It has been reported that some drugs could
enhance TRAIL-induced apoptosis [24-28], although the
underlying mechanisms remain unclear.
Discussion
In this study, by utilizing a tetracycline-controlled tran-
scriptional silencer (tTS or TetR-KRAB) and the latest
generation rtTA, a single adenoviral vector carrying in
its E1 region an all-in-one Tet-On system with an auto-
regulatory loop was successfully constructed to furtherFigure 4 Growth inhibitory effects of adenovirus encoding sTRAIL cel
were treated with PBS (mock), Ad5-E1-eGFP, Ad5-E1-sTRAIL-E3-eGFP and A
presence or absence of Dox. (B) U87 MG cells were treated similarly but w
by MTT assay three days post-transduction. Experiments were repeated fouimprove the regulational properties of the Ad-mediated
Tet-On system. This new system displayed improved
Dox-inducible gene expression in terms of low basal ex-
pression, high induced expression and high responsive-
ness to Dox. To our knowledge, this is the first reported
adenovirus-based, all-in-one Tet-On system with a large
packaging size for transgenes up to 2.0 kb. Furthermore,
the adenovirus that expresses soluble TRAIL under the
control of this novel Tet-On system showed tumor-
derived cells inhibitory activity in SW480 cells only under
induced conditions.
A single Ad vector carrying the Tet-On regulation system
could facilitate more practical and widespread application
of the Ad vector. Some studies have used IRES-mediated
bicistronic units for rtTA and tTS expression in the con-
text of an Ad vector; however, no consistent regulational
properties were observed in this system [15,16]. An Ad-
mediated Tet-On system containing three expression cas-
settes (the gene of interest, rtTA2S-S2, and tTS) in the
same vector was shown to display improved inducible
gene expression [15]. However, the space for therapeutic
transgenes was limited in this system. In addition, thels under the control of different Tet-On systems. (A) SW480 cells
d5-E1-KRAB-Bi-Tet-On-sTRAIL-E3-eGFP, respectively, at 250 MOI in the
ith a less dose of virus at 100 MOI. Cell growth inhibition was analyzed
r times; *P < 0.05, **P < 0.01.
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in this system did not show any Dox-induced luciferase
production. In contrast, in our study, the adenovirus that
carries a bidirectional promoter for rtTA2S-M2 and trans-
gene expression displayed efficient inducible transgene ex-
pression with a regulational factor of up to 137, a low
basal activity, and a maximum transgene expression level
that is comparable to that of a CMV-driven non-inducible
luciferase-expressing vector.
TRAIL can selectively induce apoptosis in many hu-
man cancer cells [18,19]. However, recent studies have
shown TRAIL to be toxic to normal liver cells, keratino-
cytes, brain cells, prostate epithelial cells, as well as neu-
trophils [20-23]. Hence regulated TRAIL gene expression
is critical in cancer gene therapy to prevent toxicity and
optimize therapeutic outcomes. In addition, the regulated
expression of sTRAIL in this study improved AD pack-
aging probably due to the decreased cytotoxicity of
sTRAIL. As expected, the sTRAIL-expressing adenovirus
showed inhibition of Dox-induced tumor-derived cells
growth.
Recently, genome editing techniques, including ZFN
[29], TALEN [30] and CRISPR/Cas9 [31], have been
widely used for gene functional analysis and gene therapy
study. One of the key issues about these techniques is the
spatiotemporal control of the nuclease expression to re-
duce off-target effects. The novel Tet-On system may be
used to control the expression of ZFN, TALEN or Cas9 so
that a desired level of nuclease expression can be reached
at the right location and the right time, and therefore, the
toxicity caused by nuclease can be minimized.
Conclusions
We constructed a novel, single Ad vector carrying in its
E1 region an all-in-one Tet-On system with an autoregu-
latory loop. This system displayed tight regulation of
transgene expression in vitro, and thus has great poten-
tial for a variety of applications, including gene therapy
and the study of gene function.
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